share_log

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Redhill Biopharma | 6-K：外国发行人报告
美股SEC公告 ·  08/01 07:08

Moomoo AI 已提取核心信息

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on August 1, 2024, the publication of positive Phase 3 study data for RHB-104 in the treatment of Crohn's disease. The study, which included 331 patients and was conducted across over 100 sites globally, demonstrated a 64% increase in efficacy when RHB-104 was added to the standard of care compared to the standard of care alone. The primary endpoint of clinical remission at week 26 was achieved by 36.7% of patients treated with RHB-104 versus 22.4% of those receiving a placebo, with a safety profile similar to placebo. The study's lead investigator, Dr. David Y. Graham, highlighted the potential of RHB-104 as an effective treatment for Crohn's disease, which could serve as an add-on therapy for patients not responding to current treatments. The Crohn's disease market was valued at over $13 billion in 2023. RedHill's CEO, Dror Ben-Asher, expressed the company's commitment to advancing the development of RHB-104 and exploring partnership models to bring this treatment to market.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on August 1, 2024, the publication of positive Phase 3 study data for RHB-104 in the treatment of Crohn's disease. The study, which included 331 patients and was conducted across over 100 sites globally, demonstrated a 64% increase in efficacy when RHB-104 was added to the standard of care compared to the standard of care alone. The primary endpoint of clinical remission at week 26 was achieved by 36.7% of patients treated with RHB-104 versus 22.4% of those receiving a placebo, with a safety profile similar to placebo. The study's lead investigator, Dr. David Y. Graham, highlighted the potential of RHB-104 as an effective treatment for Crohn's disease, which could serve as an add-on therapy for patients not responding to current treatments. The Crohn's disease market was valued at over $13 billion in 2023. RedHill's CEO, Dror Ben-Asher, expressed the company's commitment to advancing the development of RHB-104 and exploring partnership models to bring this treatment to market.
2024年8月1日，专门从事生物制药的redhill biopharma公司宣布，其对于治疗克罗恩病的RHb-104的三期研究数据为阳性。该研究涉及到331名患者，分布于全球100多个地点进行，结果表明，当RHb-104与标准治疗相比，疗效增加了64%。在第26周，临床缓解的主要终点指标，RHb-104的治疗患者达到了36.7%，而接受安慰剂的患者只有22.4%，安全性与安慰剂相似。该研究主要负责人，graham博士强调了RHb-104作为治疗克罗恩病的有效方法，可用作不应对当前治疗有效的患者的附加治疗。2023年，克罗恩病市场价值超过130亿美元。redhill biopharma的首席执行官Dror Ben-Asher表示了该公司致力于推进RHb-104的开发并探索合作模式以将该治疗方法带到市场上。
2024年8月1日，专门从事生物制药的redhill biopharma公司宣布，其对于治疗克罗恩病的RHb-104的三期研究数据为阳性。该研究涉及到331名患者，分布于全球100多个地点进行，结果表明，当RHb-104与标准治疗相比，疗效增加了64%。在第26周，临床缓解的主要终点指标，RHb-104的治疗患者达到了36.7%，而接受安慰剂的患者只有22.4%，安全性与安慰剂相似。该研究主要负责人，graham博士强调了RHb-104作为治疗克罗恩病的有效方法，可用作不应对当前治疗有效的患者的附加治疗。2023年，克罗恩病市场价值超过130亿美元。redhill biopharma的首席执行官Dror Ben-Asher表示了该公司致力于推进RHb-104的开发并探索合作模式以将该治疗方法带到市场上。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间